We congratulate the authors for the excellent review, not only restricted to recently approved therapies, on the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) (1). However, it is our opinion that some aspects that currently affect our medical practice merit further commentary.

中文翻译：

---

在纳入美国食品和药物管理局批准的治疗系统性硬化症相关间质性肺病之前需要考虑的其他要点

我们祝贺作者对系统性硬化症相关间质性肺病 (SSc-ILD) 的治疗进行了出色的审查，不仅限于最近批准的疗法 (1)。然而，我们认为目前影响我们医疗实践的某些方面值得进一步评论。